The University of Chicago Header Logo

Connection

Michael Charlton to Adult

Back to Details
This is a "connection" page, showing publications Michael Charlton has written about Adult.
Michael Charlton
Connection Strength
1.450
Adult
  1. Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 10; 10(10):1198-1208.
    View in: PubMed
    Score: 0.052
  2. Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes. Liver Transpl. 2021 07; 27(7):1019-1031.
    View in: PubMed
    Score: 0.052
  3. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation. 2021 06 01; 105(6):1285-1290.
    View in: PubMed
    Score: 0.052
  4. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. J Gastroenterol. 2020 Jul; 55(7):722-730.
    View in: PubMed
    Score: 0.048
  5. Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. Transplantation. 2017 12; 101(12):2873-2882.
    View in: PubMed
    Score: 0.041
  6. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
    View in: PubMed
    Score: 0.038
  7. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
    View in: PubMed
    Score: 0.034
  8. Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study. Am J Gastroenterol. 2015 Aug; 110(8):1126-33.
    View in: PubMed
    Score: 0.034
  9. Current epidemiology of hepatitis E virus infection in the United States: low seroprevalence in the National Health and Nutrition Evaluation Survey. Hepatology. 2014 Sep; 60(3):815-22.
    View in: PubMed
    Score: 0.032
  10. Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events. Liver Transpl. 2014 Jul; 20(7):791-7.
    View in: PubMed
    Score: 0.032
  11. Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl. 2013 Dec; 19(12):1311-7.
    View in: PubMed
    Score: 0.031
  12. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014 Apr; 60(4):691-8.
    View in: PubMed
    Score: 0.031
  13. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant. 2013 Sep; 13(9):2450-7.
    View in: PubMed
    Score: 0.030
  14. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity (Silver Spring). 2013 Sep; 21(9):1935-41.
    View in: PubMed
    Score: 0.030
  15. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012 Sep; 18(9):1029-36.
    View in: PubMed
    Score: 0.028
  16. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl. 2012 Jul; 18(7):803-10.
    View in: PubMed
    Score: 0.028
  17. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012 Mar; 18(3):323-31.
    View in: PubMed
    Score: 0.027
  18. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012 Mar; 12(3):737-44.
    View in: PubMed
    Score: 0.027
  19. Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transpl. 2011 Jun; 17(6):723-32.
    View in: PubMed
    Score: 0.026
  20. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. Obes Surg. 2011 Mar; 21(3):310-5.
    View in: PubMed
    Score: 0.025
  21. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011 Jan; 53(1):317-24.
    View in: PubMed
    Score: 0.025
  22. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl. 2011 Jan; 17(1):23-31.
    View in: PubMed
    Score: 0.025
  23. Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation. Liver Transpl. 2010 Aug; 16(8):990-8.
    View in: PubMed
    Score: 0.024
  24. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009 Jun; 9(6):1406-13.
    View in: PubMed
    Score: 0.022
  25. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology. 2009 Apr; 49(4):1375-84.
    View in: PubMed
    Score: 0.022
  26. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008 Feb; 47(2):484-92.
    View in: PubMed
    Score: 0.021
  27. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006 Jun; 43(6):1177-86.
    View in: PubMed
    Score: 0.018
  28. Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis? Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):72-3.
    View in: PubMed
    Score: 0.018
  29. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004 Sep; 10(9):1120-30.
    View in: PubMed
    Score: 0.016
  30. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.016
  31. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
    View in: PubMed
    Score: 0.015
  32. Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant. 2003 Jul; 3(7):885-90.
    View in: PubMed
    Score: 0.015
  33. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl. 2002 Sep; 8(9):814-21.
    View in: PubMed
    Score: 0.014
  34. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 Jul; 8(7):623-9.
    View in: PubMed
    Score: 0.014
  35. Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States. Transplantation. 2022 10 01; 106(10):2006-2018.
    View in: PubMed
    Score: 0.014
  36. Preservation solutions for static cold storage in donation after circulatory death and donation after brain death liver transplantation in the United States. Liver Transpl. 2022 09; 28(9):1454-1462.
    View in: PubMed
    Score: 0.014
  37. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002 Apr; 35(4):898-904.
    View in: PubMed
    Score: 0.014
  38. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open. 2022 03 30; 12(3):e056159.
    View in: PubMed
    Score: 0.014
  39. Mandatory Hepatology Education for Internal Medicine Residents: Long-Term Effects and Implications for Workforce Needs. Hepatol Commun. 2021 11; 5(11):1953-1963.
    View in: PubMed
    Score: 0.013
  40. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 2001 Jul; 7(7):608-14.
    View in: PubMed
    Score: 0.013
  41. Simultaneous Heart-Liver Transplantation for Congenital Heart Disease in the United States: Rapidly Increasing With Acceptable Outcomes. Hepatology. 2021 04; 73(4):1464-1477.
    View in: PubMed
    Score: 0.013
  42. Impact of nutritional status on outcomes after liver transplantation. Transplantation. 2000 Nov 15; 70(9):1347-52.
    View in: PubMed
    Score: 0.012
  43. Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency. Am J Transplant. 2021 03; 21(3):1039-1055.
    View in: PubMed
    Score: 0.012
  44. The effect of insulin on human small intestinal mucosal protein synthesis. Gastroenterology. 2000 Feb; 118(2):299-306.
    View in: PubMed
    Score: 0.012
  45. Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. J Heart Lung Transplant. 2019 09; 38(9):997-999.
    View in: PubMed
    Score: 0.011
  46. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Hepatology. 2019 06; 69(6):2381-2395.
    View in: PubMed
    Score: 0.011
  47. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl. 2019 04; 25(4):598-609.
    View in: PubMed
    Score: 0.011
  48. Role of hyperglucagonemia in catabolism associated with type 1 diabetes: effects on leucine metabolism and the resting metabolic rate. Diabetes. 1998 Nov; 47(11):1748-56.
    View in: PubMed
    Score: 0.011
  49. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019 01; 70(1):133-141.
    View in: PubMed
    Score: 0.011
  50. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998 Sep; 28(3):823-30.
    View in: PubMed
    Score: 0.011
  51. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology. 1998 Sep; 28(3):839-42.
    View in: PubMed
    Score: 0.011
  52. Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. J Hepatol. 2018 09; 69(3):617-625.
    View in: PubMed
    Score: 0.010
  53. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018 10; 38(10):1849-1859.
    View in: PubMed
    Score: 0.010
  54. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight. 2018 01 25; 3(2).
    View in: PubMed
    Score: 0.010
  55. Hepatitis G virus infection in patients transplanted for cryptogenic cirrhosis: red flag or red herring? Transplantation. 1998 Jan 15; 65(1):73-6.
    View in: PubMed
    Score: 0.010
  56. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 01; 67(1):328-357.
    View in: PubMed
    Score: 0.010
  57. Skeletal muscle myosin heavy chain synthesis in type 1 diabetes. Diabetes. 1997 Aug; 46(8):1336-40.
    View in: PubMed
    Score: 0.010
  58. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg. 1997 Jul; 3(4):359-64.
    View in: PubMed
    Score: 0.010
  59. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831.
    View in: PubMed
    Score: 0.010
  60. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017 03; 15(3):421-430.e6.
    View in: PubMed
    Score: 0.009
  61. Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah. Dig Dis Sci. 2016 12; 61(12):3627-3632.
    View in: PubMed
    Score: 0.009
  62. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016 10; 1(2):122-132.
    View in: PubMed
    Score: 0.009
  63. Evidence for a catabolic role of glucagon during an amino acid load. J Clin Invest. 1996 Jul 01; 98(1):90-9.
    View in: PubMed
    Score: 0.009
  64. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
    View in: PubMed
    Score: 0.009
  65. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
    View in: PubMed
    Score: 0.009
  66. Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infect Dis. 2015 Sep 02; 15:371.
    View in: PubMed
    Score: 0.009
  67. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl. 2015 Feb; 21(2):248-57.
    View in: PubMed
    Score: 0.008
  68. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int. 2014 Sep; 34(8):1259-66.
    View in: PubMed
    Score: 0.008
  69. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl. 2013 Aug; 19(8):887-95.
    View in: PubMed
    Score: 0.008
  70. Measurement and analysis of 8-hour time-weighted average sound pressure levels in a vivarium decontamination facility. Arch Environ Occup Health. 2013; 68(3):173-9.
    View in: PubMed
    Score: 0.007
  71. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013 Feb; 13(2):363-8.
    View in: PubMed
    Score: 0.007
  72. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr; 56(4):1838-44.
    View in: PubMed
    Score: 0.007
  73. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci. 2012 Apr; 57(4):952-7.
    View in: PubMed
    Score: 0.007
  74. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011 May; 17(5):528-38.
    View in: PubMed
    Score: 0.006
  75. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2010 Dec; 20(12):1698-709.
    View in: PubMed
    Score: 0.006
  76. Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol. 2010 Sep; 44(8):e178-85.
    View in: PubMed
    Score: 0.006
  77. Daclizumab induction therapy in liver transplant recipients with renal insufficiency. Aliment Pharmacol Ther. 2010 Sep; 32(6):776-86.
    View in: PubMed
    Score: 0.006
  78. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009 Jul 27; 88(2):219-25.
    View in: PubMed
    Score: 0.006
  79. Asynchronous, out-of-sequence, transcontinental chain kidney transplantation: a novel concept. Am J Transplant. 2009 Sep; 9(9):2180-5.
    View in: PubMed
    Score: 0.006
  80. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007 Jun 27; 83(12):1639-42.
    View in: PubMed
    Score: 0.005
  81. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007 Mar; 5(3):394-402; quiz 267.
    View in: PubMed
    Score: 0.005
  82. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 2006 Sep; 12(9):1381-9.
    View in: PubMed
    Score: 0.005
  83. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol. 2005 Apr; 100(4):874-8.
    View in: PubMed
    Score: 0.004
  84. Hypophosphatemia after right hepatectomy for living donor liver transplantation. Can J Gastroenterol. 2004 Dec; 18(12):729-33.
    View in: PubMed
    Score: 0.004
  85. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis. 2002 Oct 15; 35(8):974-81.
    View in: PubMed
    Score: 0.004
  86. Origin of adenocarcinoma in a transplanted liver determined by microsatellite analysis. Hum Pathol. 2002 Apr; 33(4):435-6.
    View in: PubMed
    Score: 0.003
  87. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001 Apr; 7(4):302-10.
    View in: PubMed
    Score: 0.003
  88. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000 Feb; 163(2):524-7.
    View in: PubMed
    Score: 0.003
  89. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999 Apr; 29(4):1050-6.
    View in: PubMed
    Score: 0.003
  90. The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Apr; 94(4):1000-5.
    View in: PubMed
    Score: 0.003
  91. Cancer in young people in the north of England, 1968-85: analysis by census wards. J Epidemiol Community Health. 1993 Apr; 47(2):109-15.
    View in: PubMed
    Score: 0.002
  92. Factors influencing mortality and morbidity following oesophageal resection. Eur J Cardiothorac Surg. 1989; 3(5):419-23; discussion 424.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.